Onxeo Announces its Financial Agenda for 2023

Paris (France), January 27, 2023 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced its financial agenda for 2023.


Event Date *
Extraordinary general meeting Monday, February 6, 2023
Full-year 2022 results Thursday, March 30, 2023
Annual general meeting Wednesday, May 17, 2023
Half-year 2023 results Thursday, September 28, 2023

* This preliminary agenda may be modified. Press releases are published after financial markets close.